Navigation Links
Estrogen Plays Surprise Role in Breast Cancer Treatment
Date:8/18/2009

Study finds it may slow disease if anti-estrogen therapies stop working

TUESDAY, Aug. 18 (HealthDay News) -- Researchers report that the paradoxical strategy of treating breast cancers that have become resistant to anti-estrogen therapies with estrogen actually shrank some tumors.

Not only that, but the estrogen made some of the tumors sensitive to anti-estrogen drugs once again.

The findings, reported in the Aug. 19 issue of the Journal of the American Medical Association, are preliminary, one expert cautioned.

"It's an interesting observation, but it needs to be expanded into a large trial," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "There's probably something biologically going on here that we don't quite understand. The question is, can we translate this into really clinically meaningful responses?"

"The history of treating patients with estrogen goes back to the 1940s when physicians started to treat patients with advanced breast cancer with diethylstilbestrol or DES [a synthetic estrogen]," explained Dr. Matthew Ellis, a professor of medicine at Washington University School of Medicine, an oncologist with the Siteman Cancer Center in St. Louis and a co-author of the study. "The ancient literature is full of grainy photographs with lung metastases or local, advanced breast cancer or bone metastases getting better with this paradoxical treatment."

That treatment protocol was displaced by the anti-estrogen therapy tamoxifen in the 1970s. And tamoxifen is now being replaced by stronger anti-estrogen drugs known as aromatase inhibitors.

"These drugs are a little more effective than tamoxifen ... so now you have a large population of patients with advanced breast cancer who have experienced treatment often with both estrogen-lowering agents," Ellis said. "We hypothesized that some of these patients could go back to estrogen therapy, but at a lower dose than anything looked at before."

"Giving estrogen actually was a standard-of-care practice prior to tamoxifen approval, so this trial simply confirms previously known knowledge, that estrogen can be used to treat metastatic hormone-dependent breast cancer in postmenopausal women," said Dr. Ramona Swaby, an assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia.

To try to prove the point that lower doses of estrogen might work, 66 women with metastatic breast cancer and estrogen-receptor-positive tumors were randomized to receive either 6 milligrams or 30 milligrams of oral estradiol (estrogen) each day. All women had been treated previously with an aromatase inhibitor but their disease returned.

"The 30-milligram dose produces estrogen levels typical of pregnancy, and the 6-milligram dose produces levels of non-pregnant premenopausal women [who are ovulating]," Ellis said.

The two doses were similar in effectiveness, with tumors shrinking or not growing in about 30 percent of the women.

But those taking the higher dose had more negative side effects than those in the lower-dose group, as well as a poorer quality of life, making the lower dose the overall winner.

Meanwhile, the researchers also found that they could predict which tumors would respond based on results from positron emission tomography (PET) scans taken before and after the treatment. Tumors that glowed more brightly were much more likely to respond to the estrogen treatment, according to the study.

Some of the cancers later recurred, but about a third of these women then responded again to aromatase inhibitors.

Ellis also noted that 6 milligrams of estrogen costs only about $1 a day.

No one yet knows why this effect is happens to certain women.

"The endocrine system is a complicated system of feedback loops and, under normal circumstances, women experience wild changes in estrogen levels, depending on whether they're menstruating, pregnant or postmenopausal," Ellis explained. "All this is regulated in an exquisite way, which we actually understand fairly well. These results mean the feedback loops may be corrupted in some ways."

Brooks agreed that it's "counterintuitive."

"The estrogen receptor on a cancer cell is not a simple thing," he said. "Aromatase inhibitors may somehow allow the cells to reactivate certain [hormone] receptors [on the tumor] that may actually be different than they were to start with."

The researchers said they were planning further studies to see which group of women might benefit most from the protocol.

More information

The National Cancer Institute has more on treating breast cancer.



SOURCES: Matthew J. Ellis, M.B., BChir., Ph.D., professor, medicine, Washington University School of Medicine, and oncologist, Siteman Cancer Center, St. Louis; Ramona Swaby, M.D., assistant professor, medical oncology, Fox Chase Cancer Center, Philadelphia; Jay Brooks, chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Aug. 19, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New link between estrogen and breast cancer
2. UCLA study identifies designer estrogen as potential MS drug
3. Cholesterol byproduct blocks heart health benefits of estrogen
4. Gene May Influence Breast Cancer-Estrogen Link
5. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
6. Estrogen Levels in Blood Predict Breast Cancers Return
7. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
8. New study finds adverse effects of estrogen replacement therapy are related to the dose
9. Estrogen Supplements May Raise Odds of Benign Breast Disease
10. Estrogen therapy increases benign breast disease risk
11. Previously unseen switch regulates breast cancer response to estrogen
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen Plays Surprise Role in Breast Cancer Treatment
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: